DE69320206D1 - Paclitaxel enthaltende injizierbare zusammensetzung - Google Patents

Paclitaxel enthaltende injizierbare zusammensetzung

Info

Publication number
DE69320206D1
DE69320206D1 DE69320206T DE69320206T DE69320206D1 DE 69320206 D1 DE69320206 D1 DE 69320206D1 DE 69320206 T DE69320206 T DE 69320206T DE 69320206 T DE69320206 T DE 69320206T DE 69320206 D1 DE69320206 D1 DE 69320206D1
Authority
DE
Germany
Prior art keywords
taxol
solution
injectable composition
acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69320206T
Other languages
English (en)
Other versions
DE69320206T2 (de
Inventor
David Carver
Timothy Prout
Hernita Ewald
Robyn Elliott
Paul Handreck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayne Pharma USA Inc
Original Assignee
Tapestry Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25644377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69320206(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tapestry Pharmaceuticals Inc filed Critical Tapestry Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69320206D1 publication Critical patent/DE69320206D1/de
Publication of DE69320206T2 publication Critical patent/DE69320206T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
DE69320206T 1992-11-27 1993-11-18 Paclitaxel enthaltende injizierbare zusammensetzung Revoked DE69320206T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPL607492 1992-11-27
US99550192A 1992-12-22 1992-12-22
PCT/US1993/011209 WO1994012031A1 (en) 1992-11-27 1993-11-18 Injectable composition

Publications (2)

Publication Number Publication Date
DE69320206D1 true DE69320206D1 (de) 1998-09-10
DE69320206T2 DE69320206T2 (de) 1999-02-11

Family

ID=25644377

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69333605T Revoked DE69333605T2 (de) 1992-11-27 1993-11-18 Stabile injizierbare Paclitaxel Lösung
DE69320206T Revoked DE69320206T2 (de) 1992-11-27 1993-11-18 Paclitaxel enthaltende injizierbare zusammensetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69333605T Revoked DE69333605T2 (de) 1992-11-27 1993-11-18 Stabile injizierbare Paclitaxel Lösung

Country Status (12)

Country Link
US (7) US5733888A (de)
EP (4) EP0674510B1 (de)
JP (1) JP2880292B2 (de)
AT (2) ATE274347T1 (de)
AU (1) AU5612694A (de)
CA (2) CA2308082A1 (de)
DE (2) DE69333605T2 (de)
DK (2) DK0835657T3 (de)
ES (2) ES2119996T3 (de)
GR (1) GR3027724T3 (de)
PT (1) PT835657E (de)
WO (2) WO1994012031A1 (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE274347T1 (de) * 1992-11-27 2004-09-15 Mayne Pharma Usa Inc Stabile injizierbare paclitaxel lösung
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
FR2710534B1 (fr) * 1994-09-28 1996-07-05 Bristol Myers Squibb Co Solvant de stabilisation, composition pharmaceutique le contenant, et son procédé de préparation.
NL9500340A (nl) * 1995-02-22 1996-10-01 Yew Tree Pharmaceuticals B V Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat.
DE19536165A1 (de) * 1995-09-28 1997-04-03 Basf Ag Verfahren zur Reinigung von alkoxylierten Fetten
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU724842B2 (en) * 1995-12-21 2000-09-28 Genelabs Technologies, Inc. Taxane composition and method
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
CA2275889C (en) 1996-12-30 2008-03-18 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
DE19983660T1 (de) 1998-10-20 2001-09-13 Ben Venue Lab Inc Verfahren zur Aufreinigung von Lösungsmitteln, die bei der Herstellung von pharmazeutischen Zusammensetzungen nützlich sind
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
EP1591437B1 (de) 1999-05-14 2009-11-25 Nereus Pharmaceuticals, Inc. Interleukin-1 und Tumornekrosefaktor-alpha Modulatoren,Synthese dieser Modulatoren und Methoden zur Anwendung dieser Modulatoren
DE19925211B4 (de) * 1999-06-01 2006-01-12 PBS Pharmaceutical Bulk Substances SA Kit zur Herstellung einer Formulierung von Paclitaxel
CO5271755A1 (es) * 2000-01-20 2003-04-30 Baker Norton Pharma Purificacion de aceites de castor polioxietilados con carbon activado
JP2003521545A (ja) * 2000-02-02 2003-07-15 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド 改良された溶解性を有するタキサン製剤
WO2001062919A1 (en) 2000-02-23 2001-08-30 Aurora Biosciences Corporation Modified fluorescent proteins
JP4922507B2 (ja) * 2000-08-10 2012-04-25 武田薬品工業株式会社 医薬組成物
AU2001278705A1 (en) 2000-08-10 2002-02-25 Takeda Chemical Industries Ltd. Pharmaceutical composition
AU2002243228B2 (en) * 2000-11-16 2007-08-02 The Regents Of The University Of California Marine actinomycete taxon for drug and fermentation product discovery
EP1337273A2 (de) * 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen enthaltend paclitaxel, dessen derivate und dessen pharmazeutisch denkbare saltze
WO2002080940A2 (en) 2001-04-06 2002-10-17 Cytorex Biosciences, Inc. Pharmacologically active strong acid solutions
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
JP2005515187A (ja) * 2001-11-26 2005-05-26 スーパージェン インコーポレイテッド ポリオキシエチル化ひまし油を使用する医薬組成物の調製方法
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
RU2004119557A (ru) * 2001-12-20 2005-04-20 Бристол-Маерс Сквибб Компани (Us) Фармацевтические композиции перорально активных производных таксана с повышенной биодоступностью
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
CA2491216C (en) * 2002-06-26 2012-01-03 Medigene Oncology Gmbh Method of producing a cationic liposomal preparation comprising a lipophilic compound
AU2003302721B2 (en) * 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) * 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
AU2003296908A1 (en) * 2002-09-27 2004-05-04 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
US20040122081A1 (en) * 2002-11-08 2004-06-24 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
WO2004072104A2 (en) * 2003-02-11 2004-08-26 Northwestern University Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon
EP1638552B1 (de) * 2003-06-20 2011-03-02 Nereus Pharmaceuticals, Inc. Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs
ZA200600473B (en) * 2003-06-20 2007-04-25 Univ California Salinosporamides and methods for use thereof
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
WO2005061474A1 (en) * 2003-12-12 2005-07-07 Quiral Química Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
ATE509018T1 (de) * 2004-01-23 2011-05-15 Nereus Pharmaceuticals Inc Als antimikrobielle mittel geeignete bisindolpyrrole
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
AU2005283141B2 (en) 2004-04-30 2012-05-10 Nereus Pharmaceuticals, Inc. (3.2.0) heterocyclic compounds and methods of using the same
US7361683B2 (en) * 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
WO2006060676A1 (en) 2004-12-03 2006-06-08 Dana Farber Cancer Institute Compositions and methods for treating neoplastic diseases
WO2006126825A1 (en) * 2005-05-23 2006-11-30 Choongwae Pharma Corporation Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection
KR20080030024A (ko) * 2005-06-17 2008-04-03 호스피라 오스트레일리아 피티와이 리미티드 도세탁셀의 약제학적 액상제제
ATE556046T1 (de) 2005-07-21 2012-05-15 Nereus Pharmaceuticals Inc Interleukin-1- und tumornekrosefaktor-a- modulatoren, synthese solcher modulatoren und verfahren unter anwendung solcher modulatoren
KR101420445B1 (ko) 2005-08-31 2014-07-16 아브락시스 바이오사이언스, 엘엘씨 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
FR2912745A1 (fr) * 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
WO2009140287A1 (en) 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US9198968B2 (en) * 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8128951B2 (en) 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
SG185389A1 (en) 2010-05-03 2012-12-28 Teikoku Pharma Usa Inc Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012130819A1 (en) 2011-03-29 2012-10-04 Sanofi Otamixaban formulations with improved stability
CA2841864A1 (en) * 2011-07-11 2013-01-17 Claude MERCURE Novel anti-cancer isocarbostyril alkaloid conjugates
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2777691A1 (de) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Reinigung der flüssigen Hilfsstoffen
JP2016513699A (ja) * 2013-03-15 2016-05-16 エピザイム，インコーポレイティド 癌の治療のための注射製剤
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices
EP3628640B1 (de) 2014-09-02 2023-08-09 Hub Therapeutics Verfahren zur herstellung eines deuterierten oder eines nichtdeuterierten moleküls und pharmazeutische formulierungen zur behandlung
US20170290765A1 (en) * 2014-09-17 2017-10-12 Epizyme, Inc. Injectable formulations for treating cancer
US10751317B2 (en) 2014-10-08 2020-08-25 Pacific Northwest Research Institute Methods and compositions for increasing the potency of antifungal agents
JP6904570B2 (ja) 2015-03-06 2021-07-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 脳腫瘍の治療方法
SG11201707127VA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
CN109516981B (zh) 2015-07-13 2019-10-22 大连万春布林医药有限公司 普那布林组合物
US10561766B2 (en) * 2015-09-15 2020-02-18 W. L. Gore & Associates, Inc. Drug composition and coating
RU2753543C1 (ru) 2016-02-08 2021-08-17 Бейондспринг Фармасьютикалс, Инк. Композиции, содержащие тукаресол или его аналоги
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
US10226423B1 (en) * 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
CA3089226A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
MX2020010036A (es) 2018-03-28 2021-03-02 Herbalife Int Of America Inc Acetilacion de polisacaridos.
BR112021005104A2 (pt) * 2018-10-16 2021-06-08 US Nano Food & Drug INC formulação de injeção intratumoral
AU2021257738A1 (en) 2020-04-13 2022-05-19 US Nano Food & Drug INC Basic chemotherapeutic intratumour injection formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS552421B2 (de) * 1971-08-06 1980-01-19
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5157049A (en) * 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
KR0158697B1 (ko) * 1990-02-15 1998-11-16 어니스트 지. 포스너 알루미나 및 비결정성 실리카 조성물을 사용하는 튀김 오일 처리 방법
TW223634B (de) * 1991-03-18 1994-05-11 Kingston David G I
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
ATE274347T1 (de) * 1992-11-27 2004-09-15 Mayne Pharma Usa Inc Stabile injizierbare paclitaxel lösung
NZ258044A (en) * 1992-11-27 1995-12-21 Faulding F H & Co Ltd Pharmaceutical composition comprising taxol, solubilising agent, an acid and an organic solvent
US5281727A (en) * 1992-11-27 1994-01-25 Napro Biotherapeutics, Inc. Method of using ion exchange media to increase taxane yields
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5733388A (en) 1994-08-11 1998-03-31 Daido Tokiushuko Kabushiki Kaisha Steel composition for bearings and method of producing the same

Also Published As

Publication number Publication date
US5733888A (en) 1998-03-31
ATE169216T1 (de) 1998-08-15
US6770670B2 (en) 2004-08-03
GR3027724T3 (en) 1998-11-30
US20040204479A1 (en) 2004-10-14
JP2880292B2 (ja) 1999-04-05
PT835657E (pt) 2004-11-30
US20030065022A1 (en) 2003-04-03
CA2149150A1 (en) 1994-06-09
EP0835657A1 (de) 1998-04-15
DK0674510T3 (da) 1999-05-10
EP1384474A1 (de) 2004-01-28
AU5612694A (en) 1994-06-22
EP0674510A4 (de) 1995-08-12
CA2149150C (en) 2000-08-01
CA2308082A1 (en) 1994-06-09
DE69320206T2 (de) 1999-02-11
US5972992A (en) 1999-10-26
ES2119996T3 (es) 1998-10-16
US6140359A (en) 2000-10-31
DK0835657T3 (da) 2005-01-10
JPH08503945A (ja) 1996-04-30
US6306894B1 (en) 2001-10-23
DE69333605T2 (de) 2005-02-03
WO1994012031A1 (en) 1994-06-09
EP0835657B1 (de) 2004-08-25
EP0674510A1 (de) 1995-10-04
DE69333605D1 (de) 2004-09-30
WO1994012030A1 (en) 1994-06-09
US5977164A (en) 1999-11-02
EP1500393A1 (de) 2005-01-26
EP0674510B1 (de) 1998-08-05
ATE274347T1 (de) 2004-09-15
ES2224200T3 (es) 2005-03-01

Similar Documents

Publication Publication Date Title
DE69320206D1 (de) Paclitaxel enthaltende injizierbare zusammensetzung
ATE201328T1 (de) Hochkonzentriertes immunglobulin-präparat und verfahren zu seiner herstellung
DE69212921T2 (de) Sonnenschutzmittel
DK47189D0 (da) Bredspektret konserveringsmiddel med synergistisk biocidvirkning
ZA924999B (en) New compositions containing taxane derivatives
DE3682208D1 (de) Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.
DE69307977T2 (de) Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
FI964285A0 (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
ATE225340T1 (de) Einschlusskomplexe von taxol oder taxotere oder taxus-extrakten und cyclodextrinen, ihre herstellung und ihre verwendung
HUT66153A (en) Pharmaceutical compositions which can be used for preventing and treating of chemotherapy-induced alopecia
PL289266A1 (en) Method of stabilizing 3-isothiazolones and compositions containing them
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
KR940008695A (ko) 안티트롬빈 iii제제
DE69206460D1 (de) Injizierbare 2-Oxindol-1-carboxamidderivate enthaltende Arzneizubereitungen.
TH1086A (th) ส่วนประกอบสารทำให้ผ้านุ่ม

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Free format text: DERZEIT KEIN VERTRETER BESTELLT

8327 Change in the person/name/address of the patent owner

Owner name: MAYNE PHARMA (USA)INC.(N.D.GES.D.STAATES DELAWARE)

8331 Complete revocation